TABLE 1.
Clinical characteristics of study subjects
| Patient code | HLA class I type
|
Viral load (copies/ml) | CD4 count (cells/μl) | Opportunistic diseasea | ||
|---|---|---|---|---|---|---|
| HLA A | HLA B | HLA Cw | ||||
| PR 1 | 2, 3 | 35, 44 | 4, 7 | 12,900 | 12 | MAC infection, AIDS dementia |
| PR 2 | 23, 68 | 7, 57 | 7 | 24,400 | 55 | HIV wasting |
| PR 3 | 1, 3 | 8, 58 | 7 | 25,362 | 329 | ⊘ |
| PR 4 | 24, 30 | 13, 40 | 6, 7 | 30,000 | 290 | ⊘ |
| PR 5 | 3, 25 | 42, 57 | 3 | 48,700 | 408 | ⊘ |
| PR 6 | 24, 68 | 7, 13 | 7, 8 | 50,600 | 488 | ⊘ |
| PR 7 | 29, 31 | 35, 40 | 2, 4 | 61,000 | 29 | ⊘ |
| PR 8 | 2, 11 | 35, 40 | 3, 4 | 96,100 | 436 | ⊘ |
| PR 9 | 2, 30 | 49, 51 | 7, 16 | 98,500 | 423 | ⊘ |
| PR 10 | 33, 68 | 15, 53 | 3, 4 | 98,800 | 28 | PCP |
| PR 11 | 1, 2 | 15, 53 | 2, 6 | 118,000 | 27 | KS |
| PR 12 | 1, 2 | 15, 44 | 3, 5 | 124,000 | 82 | PCP |
| PR 13 | 1 | 8, 57 | 6, 7 | 160,000 | 60 | ⊘ |
| PR 14 | 1, 3 | 7 | 7 | 171,000 | 277 | KS |
| PR 15 | 2, 26 | 38, 44 | 5, 12 | 200,000 | 150 | ⊘ |
| PR 16 | 1, 2 | 18, 27 | 2, 12 | 249,000 | 115 | KS |
| PR 17 | 2, 68 | 7, 44 | 7 | 269,000 | 220 | ⊘ |
| PR 18 | 2, 26 | 8, 44 | 5, 7 | 292,000 | 129 | PML |
| PR 19 | 2, 26 | 44, 45 | 5, 6 | 376,000 | 3 | MAC infection |
| PR 20 | 30, 36 | 35, 58 | 6, 7 | >500,000 | 0 | ⊘ |
| PR 21 | 29, 68 | 40, 52 | 2, 15 | >500,000 | 11 | PCP |
| PR 22 | 2, 24 | 18, 35 | 4, 7 | >500,000 | 17 | Cryptococcal meningitis |
| PR 23 | 2, 66 | 15, 41 | 14, 17 | >750,000 | 33 | Oral candidiasis |
| PR 24 | 1, 3 | 7, 57 | 6, 7 | >750,000 | 24 | PCP |
a
MAC, Mycobacterium avium complex; PCP, Pneumocystis carinii pneumonia; KS, Kaposi's sarcoma; PML, progressive multifocal leukoencephalopathy; ⊘, no opportunistic diseases.